Company news

Prelude Therapeutics Incorporated news in 2023

Prelude Therapeutics Incorporated's news releases, calls and decks from 2023, newest first.

View company

Prelude Therapeutics Announces $25 Million Private Placement

December 10, 2023

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

October 31, 2023

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

October 31, 2023

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

October 13, 2023

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

August 28, 2023

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 2, 2023

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 30, 2023

Prelude Therapeutics Announces Pricing of Public Offering

May 17, 2023

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 16, 2023

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 7, 2023

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

April 26, 2023

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

April 10, 2023

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

March 14, 2023

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

March 14, 2023

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

February 28, 2023

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

February 8, 2023

Decks in 2023